logo
logo
Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc.

NASDAQ•PRAX
CEO: Mr. Marcio Silva De'Souza M.B.A.
セクター: Healthcare
業種: Biotechnology
上場日: 2020-10-16
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
連絡先情報
99 High Street, 30th Floor, Boston, MA, 02110, United States
617-300-8460
praxismedicines.com
時価総額
$6.71B
PER (TTM)
-25.5
34.3
配当利回り
--
52週高値
$335.75
52週安値
$26.70
52週レンジ
94%
順位58Top 85.6%
2.3
F-Score
改良版 Piotroski 分析
7年ファンダメンタル
弱い • 2.3 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2019-2025

財務ダッシュボード

Q3 2025 データ

売上高

$0.00-100.00%
直近4四半期の推移

EPS

-$3.36+22.18%
直近4四半期の推移

フリーCF

-$64.74M+135.41%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Pipeline Milestones Achieved Ulixacaltamide Phase 3 results positive; FDA pre-NDA meeting set for Q4 2025; Relutrigine received Breakthrough Therapy Designation.
Major Financing Completed Company closed October 2025 public offering, raising approximately $567.0 M in net proceeds to extend operational runway.
R&D Investment Surge Nine Months R&D expenses increased $93.5 M USD, driven by significant spend increases across Cerebrum platform programs.
Cash Position Strong Cash, cash equivalents, and marketable securities totaled $389.2 M USD as of September 30, 2025, supporting near-term plans.

リスク要因

Widening Net Loss Nine Months Net Loss reached $214.4 M USD, representing a $90.2 M increase compared to the prior nine-month period.
High Operating Burn Operating cash use increased substantially; company expects continued significant operating losses for the foreseeable future.
Future Capital Dependency Future viability depends on raising substantial additional capital, as current funding is projected to last only into 2028.
Collaboration Revenue Loss Collaboration revenue dropped $1.1 M USD NME as UCB exercised its in-license option, eliminating future research obligations.

見通し

Ulixacaltamide Regulatory Path FDA Type B pre-NDA meeting for ulixacaltamide is scheduled to occur during the fourth quarter of 2025.
Vormatrigine Data Readout Expect topline results for the POWER1 efficacy study for vormatrigine in the first half of calendar year 2026.
Relutrigine Interim Analysis Planning an interim analysis of the second cohort for the ongoing EMBOLD study during the fourth quarter of 2025.
Preclinical Candidate Nomination Anticipate nominating development candidates for PRAX-080, PRAX-090, and PRAX-100 in the first half of 2026.

同業比較

売上高 (TTM)

ACADIA Pharmaceuticals Inc.ACAD
$1.05B
+12.7%
Ligand Pharmaceuticals IncorporatedLGND
$251.23M
+64.8%
Soleno Therapeutics, Inc.SLNO
$98.68M
+0.0%

粗利益率 (最新四半期)

Dianthus Therapeutics, Inc.DNTH
100.0%
+0.0pp
Crinetics Pharmaceuticals, Inc.CRNX
100.0%
+0.0pp
Oculis Holding AGOCS
100.0%
+0.0pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
PRAX$6.71B-25.5-66.9%0.1%
KYMR$6.50B-24.4-33.4%7.6%
IMVT$5.24B-10.1-65.8%0.0%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
N/M
売上高の変動が大きい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年2月19日
|
EPS:-$3.00
|
売上高:$256.09K
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月5日|
    売上高: $0.00-100.0%
    |
    EPS: $-3.36+22.2%
    不明

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月4日|
    売上高: $0.00-100.0%
    |
    EPS: $-3.31+90.2%
    不明

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月2日|
    売上高: $0.00-100.0%
    |
    EPS: $-3.29+15.8%
    不明

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月28日|
    売上高: $8.55M+249.5%
    |
    EPS: $-10.21+45.4%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月6日|
    売上高: $302.00K-35.5%
    |
    EPS: $-2.75+0.9%
    予想を下回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月13日|
    売上高: $357.00K-54.3%
    |
    EPS: $-1.74-76.4%
    予想通り

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月13日|
    売上高: $431.00K-36.9%
    |
    EPS: $-2.84-73.2%
    予想を下回る

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年3月5日|
    売上高: $2.45M+0.0%
    |
    EPS: $-18.69+73.0%
    予想を下回る